Following a series of pilot animal studies on potential medical indications of its Closed Loop System (the CLS Neuromodulator), Victhom Human Bionics (TSE: VHB) has filed a U.S. provisional patent application entitled "Bio-Interfacing Closed Loop Platform for the Correction of Disorders and/or Deficiencies in a Physiological Process Such as Sleep apnea", aimed at the management of respiratory disorders such as sleep apnea.

Sleep apnea is defined as an intermittent cessation of airflow through the nose and mouth during sleep.

According to Mr. Stephane Bedard, Founder and Chief Operating Officer:

"The studies that were conducted demonstrate that our technology is efficient for the recognition of respiratory deficiencies and are an encouraging indication that our CLS Neuromodulator and its components such as the Neurocuff™ and the Neurolink™ could be developed for several other indications considered as unmet medical needs."

The said patent application is designed to protect the use of the CLS Neuromodulator that includes neurosensing and neurostimulating systems (NSS) directly interfacing with the peripheral nervous system (PNS).

The CLS Neuromodulator may provide beneficial therapeutic effects to patients who suffer from respiratory disorders. The electrical stimulation signal is adjusted in accordance with the signals detected by the CLS Neuromodulator, which is designed to treat respiratory deficiencies.

Gee, that sound really bionic!

Find more details from the press release (a pdf file).